$120.01
0.26% yesterday
NYSE, Jun 27, 10:10 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock News

Neutral
GlobeNewsWire
2 days ago
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Neutral
GlobeNewsWire
3 days ago
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.
Positive
Seeking Alpha
3 days ago
Novartis AG could be a qualitative investment with a margin of safety. The drugmaker arguably has the balanced commercial drug portfolio and drug pipeline needed to sustain growth in the years ahead. Novartis carries a very manageable debt load for a company of its size.
Neutral
GlobeNewsWire
16 days ago
Basel, June 12, 2025 – Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with Hb levels ≥10g/dL who switched from anti-C5 therapies (eculizumab or ravulizumab)1. After 24 weeks of treatment with Fabhalta, the Hb level im...
Neutral
The Motley Fool
22 days ago
When broader equities are volatile, it's tempting to focus on what's going to happen in the near term. That's why some investors resort to panic selling -- they anticipate that things will get even worse than they already are.
Positive
Reuters
26 days ago
Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage for a drug technology that the drugmaker has pioneered.
Positive
WSJ
26 days ago
Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Neutral
GlobeNewsWire
26 days ago
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1    Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows pote...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today